<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147147</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG9206-2</org_study_id>
    <secondary_id>C000000067</secondary_id>
    <nct_id>NCT00147147</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)</brief_title>
  <official_title>Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <brief_summary>
    <textblock>
      To evaluate the survival benefit of adjuvant chemotherapy after curative resection with D2 or
      greater lymph node dissection in T3-4 gastric cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To evaluate the survival benefit of adjuvant chemotherapy after curative resection
      in serosa-positive gastric cancer patients, a multicenter phase III clinical trial was
      conducted by 13 participating centers in Japan. Methods: From January 1993 to March 1998, 268
      patients were randomized to either adjuvant chemotherapy (135 pts) or surgery alone (133
      pts). The chemotherapy comprised intraperitoneal cisplatin 70 mg/m2 before closing the
      abdomen, and after surgery intravenous cisplatin 70 mg/m2 (day 14) and 5-fluorouracil (5-FU)
      700 mg/m2 daily (day 14-16), and oral FU (UFT) 267 mg/m2 daily from 4 weeks after surgery for
      the next 12 months. The primary endpoint was overall survival. Relapse-free survival and the
      site of recurrence were secondary endpoints.

      Comparison: gastrectomy with D2 or greater lymph node dissection versus gastrectomy with
      adjuvant chemotherapy after curative resection in serosa-positive gastric cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1993</start_date>
  <completion_date>March 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the site of recurrence</measure>
  </secondary_outcome>
  <enrollment>280</enrollment>
  <condition>Gastric Neoplasm</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy with D2 or greater lymph node dissection</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastrectomy+ chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Curative operation with D2 or greater lymph node dissection

          2. Histologically proven gastric adenocarcinoma

          3. Macroscopically serosa-positive (T3-4)

          4. No metastases to level 3 - 4 lymph nodes station (N0-2)

          5. 75 years or younger

          6. Negative peritoneal lavage cytology

          7. Adequate organ function WBC &gt;=4000/mm3,Hb &gt;=11.0g/dl,Plt &gt;=100.000/mm3,AST/ALT, T.Bil,
             BUN, Creatinine &lt;=2.5 x Normal Upper Limit,Creatinine clearance &lt;=70 ml/min

          8. Written informed consent

        Exclusion Criteria:

          1. Prior chemotherapy or radiotherapy

          2. Synchronous or metachronous malignancy in other organs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Furukawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sakai Municipal Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastric Surgery Division, National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <keyword>gastric neoplasm</keyword>
  <keyword>gastrectomy</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>randomized trial</keyword>
  <keyword>T3 and T4 carcinoma of the stomach/Gastric Neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

